Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Biocryst Pharmaceuticals Inc shares valued at $68,544 were purchased by SANDERS MACHELLE on Nov 13 ’25. At $7.14 per share, SANDERS MACHELLE acquired 9,600 shares.
Also, HEGGIE THERESA sold 70,000 shares, netting a total of over 595,868 in proceeds. Following the sale of shares at $8.51 each, the insider now holds 65,352 shares.
Before that, HEGGIE THERESA had added 70,000 shares to its account. In a trade valued at $595,871, the Director bought Biocryst Pharmaceuticals Inc shares for $8.51 each.
Analysts at Evercore ISI downgraded the stock from ‘”an Outperform”‘ to ‘”an In-line”‘ outlook in a report released in early October. As of April 29, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for BCRX. Earlier on February 25, 2025, Wedbush initiated its rating. Their recommendation was “an Outperform” for BCRX stock.
Analyzing BCRX Stock Performance
On last trading session, Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] plunged -3.90% to $6.9. The stock’s lowest price that day was $6.9, but it reached a high of $7.23 in the same session. During the last five days, there has been a drop of approximately -1.85%. Over the course of the year, Biocryst Pharmaceuticals Inc shares have dropped approximately -15.75%. Shares of the company reached a 52-week high of $11.31 on 06/04/25 and a 52-week low of $6.00 on 10/14/25.
Support And Resistance Levels for Biocryst Pharmaceuticals Inc (BCRX)
According to the 24-hour chart, there is a support level at 6.79, which, if violated, would cause prices to drop to 6.68. In the upper region, resistance lies at 7.12. The next price resistance is at 7.34. RSI (Relative Strength Index) is 42.95 on the 14-day chart, showing neutral technical sentiment.
Is Biocryst Pharmaceuticals Inc subject to short interest?
Stocks of Biocryst Pharmaceuticals Inc saw a sharp rise in short interest on 2025-10-31 jumping by 4.9 million shares to 32.47 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 27.57 million shares. A jump of 15.09% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.91 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.91.
Which companies own the most shares of Biocryst Pharmaceuticals Inc (BCRX)?
In terms of Biocryst Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 15 in the next 12 months, up nearly 108.91% from the previous closing price of $7.18. Analysts anticipate Biocryst Pharmaceuticals Inc stock to reach 25 by 2025, with the lowest price target being 8. In spite of this, 13 analysts ranked Biocryst Pharmaceuticals Inc stock as Buy at the end of 2025. On November 20, 2023, JP Morgan assigned a price target of “an Overweight” to the stock and resumed coverage with a $10.
